Latest news with #AbYlink™
Business Wire
12-06-2025
- Business
- Business Wire
Debiopharm and Alkyon Therapeutics Announce Research Collaboration to Advance the Next Generation of Radioligand Therapies
MARTIGNY, Switzerland & LAUSANNE, Switzerland & SAN DIEGO--(BUSINESS WIRE)--Debiopharm ( a privately-owned Swiss biopharmaceutical company committed to establishing tomorrow's standard of care to cure cancer and infectious diseases and Alkyon Therapeutics, Inc., a biotechnology company pioneering precision-targeted therapies, today announced the signing of a co-research agreement to evaluate the feasibility of developing targeted radioligand therapies (RLTs) using Debiopharm's proprietary AbYlink™ conjugation technology for Alkyon's modular antibody platform directed against undisclosed tumor-associated antigens. This collaboration marks a promising step toward a new generation of RLTs designed to deliver potent radiation targeted directly to cancer cells while minimizing damage to healthy tissues. By leveraging the unique strengths of both platforms, the goal is to create more effective, better-tolerated cancer treatments that improve patient quality of life and expand therapeutic options for difficult-to-treat tumors. AbYLink™ technology enables regio-selective lysine conjugation, ensuring the radioligand avoids the target binding site and facilitating streamlined, consistent manufacturing. 'We're intrigued to explore the potential of applying AbYlink™ conjugation technology to the radio-oncology field,' expressed Frederic Levy, Chief Scientific Officer, Debiopharm. 'Leveraging our innovative conjugation platform with Alkyon's engineered antibody scaffolds could open new possibilities for next-generation radiopharmaceuticals with enhanced precision and therapeutic impact.' 'This collaboration reflects our shared commitment to expanding the potential of radioligand therapies,' said Benjamin Titz, Co-Founder and CEO of Alkyon Therapeutics. 'By applying AbYlink™ to our specialized antibody scaffolds and targeting strategies tailored to the unique architecture of solid tumors, we aim to unlock new therapeutic possibilities and advance care for patients with difficult-to-treat solid tumors.' About AbYlink™ AbYlink™ is a versatile and rapid regio-selective chemical conjugation technology for use in preparing diagnostic or therapeutic conjugates. This one-step method results in stable conjugation at defined and invariable sites on the Fc domain of an antibody or the like, with no impact on antigen-binding regions. It enables a seamless and reproducible conjugation of payloads (e.g., a chelator for radiolabeling, a fluorescent dye or a drug) to antibodies or ADCs. The universal applicability of the technology has been demonstrated for various antibody isotypes and payloads. About Alkyon Therapeutics, Inc. Alkyon Therapeutics, Inc. (AlkyonTx™) is a biotechnology company developing next-generation radioligand therapies (RLTs) for solid tumors. By combining precision-engineered antibodies with advanced radiochemistry and dosimetry technologies, Alkyon aims to overcome barriers such as immune exclusion and drug resistance in difficult-to-treat cancers. Its modular platform supports monotherapies, bispecifics, and rational combinations designed to enable differentiated clinical benefit and scalable product development. Debiopharm's commitment to patients Debiopharm aims to develop innovative therapies that target high unmet medical needs primarily in oncology and bacterial infections. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds and technologies for in-licensing, clinically demonstrate their safety and efficacy, and then hand stewardship to large pharmaceutical commercialization partners to maximize patient access globally. For more information, please visit
Yahoo
24-04-2025
- Business
- Yahoo
Debiopharm and Oncodesign Services Launch Strategic Collaboration to Propel Radiopharmaceuticals in Preclinical Research
MARTIGNY, Switzerland & DIJON, France, April 24, 2025--(BUSINESS WIRE)--Debiopharm Research & Manufacturing S.A. (Debiopharm, a Swiss-based global biopharmaceutical company aiming to cure cancer and infectious diseases, and Oncodesign Services ( a leading CRO specialized in drug discovery and preclinical services, announce the execution of a license agreement for the use of the AbYlink™ technology for preclinical services. AbYlink™ is a regio-selective bioconjugation technology ideally suited for preparing conjugates for use in therapeutic and non-invasive diagnostic applications. Oncodesign Services will use this cutting-edge technology to prepare antibody chelator conjugates for use in preclinical studies to gain insights into the predictive effectiveness of novel treatment approaches in Molecular Radiotherapy, and particularly Radioimmunotherapy in the context of cancer. A joint poster will be presented at the AACR Annual Meeting 2025 to demonstrate the use of the non-invasive technology in Radioimmunotherapy, targeting animal models bearing HER2+ tumors. "We have demonstrated the effectiveness of this powerful technology to rapidly and covalently conjugate any off-the-shelf antibody in a single step with an imaging agent. Our strategic collaboration with Oncodesign Services allows broader access to and usage of non-invasive imaging applications and provides an innovative solution to biotech and pharma partners to integrate imagery in the development of new antibody- and ADC-based therapeutics," commented Frédéric Lévy, Chief Scientific Officer at Debiopharm. Aidan Synnott, CEO of Oncodesign Services, said, "We are pleased to integrate this cutting-edge technology into our portfolio for our clients. The AbYlink™ technology gives the advantage of generating reproducible batches of bioconjugated antibodies and ADCs that secure specificity and efficacy of targeted radiotherapy." About AbYlink™ AbYlink™ is a versatile and rapid regio-selective chemical conjugation technology for use to prepare diagnostic or therapeutic conjugates. This one-step method results in stable conjugation at defined and invariable sites on the Fc domain of an antibody or the like, with no impact on antigen-binding regions. It enables a seamless and reproducible conjugation of payloads (e.g., a chelator for radiolabeling, a fluorescent dye or a drug) to antibodies or ADCs. The universal applicability of the technology has been demonstrated for various antibody isotypes and payloads. About Debiopharm Research & Manufacturing Debiopharm Research & Manufacturing manufactures treatments for prostate cancer, breast cancer and precocious puberty, namely at its Martigny facility, where it employs two hundred people. It is a subsidiary of the pharmaceutical company Debiopharm, headquartered in Lausanne, Switzerland. Debiopharm is an innovative company, devoting over 90% of its resources to innovation and the development of new drugs. Its mission is to develop innovative therapies that target high unmet medical needs in oncology and infectious diseases. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds and technologies for in-licensing, clinically demonstrate their safety and efficacy, and then select pharmaceutical commercialization partners to maximize patient access globally. For more information, please visit: Follow us on LinkedIn About Oncodesign Services Oncodesign Services is a contract research organization specializing in drug discovery and preclinical development. The company works with global biopharma partners to advance therapies in oncology, inflammation and infectious diseases through integrated services in protein sciences, structural biology, medicinal chemistry, pharmaco-imaging, DMPK and in vivo/in vitro pharmacology. Oncodesign Services has European facilities in France and the Netherlands. More information on the website Follow us on LinkedIn View source version on Contacts Debiopharm Research & Manufacturing Contact: Dawn Bonine – Head of Tel: +41 (0)21 321 01 11 Oncodesign Services Contact: Nathalie Dubois – Marketing Managercomms@ Tel.: +33 (0)3 80 78 82 60 Sign in to access your portfolio
Business Wire
24-04-2025
- Business
- Business Wire
Debiopharm and Oncodesign Services Launch Strategic Collaboration to Propel Radiopharmaceuticals in Preclinical Research
MARTIGNY, Switzerland & DIJON, France--(BUSINESS WIRE)--Debiopharm Research & Manufacturing S.A. (Debiopharm, a Swiss-based global biopharmaceutical company aiming to cure cancer and infectious diseases, and Oncodesign Services ( a leading CRO specialized in drug discovery and preclinical services, announce the execution of a license agreement for the use of the AbYlink™ technology for preclinical services. AbYlink™ is a regio-selective bioconjugation technology ideally suited for preparing conjugates for use in therapeutic and non-invasive diagnostic applications. Oncodesign Services will use this cutting-edge technology to prepare antibody chelator conjugates for use in preclinical studies to gain insights into the predictive effectiveness of novel treatment approaches in Molecular Radiotherapy, and particularly Radioimmunotherapy in the context of cancer. A joint poster will be presented at the AACR Annual Meeting 2025 to demonstrate the use of the non-invasive technology in Radioimmunotherapy, targeting animal models bearing HER2+ tumors. 'We have demonstrated the effectiveness of this powerful technology to rapidly and covalently conjugate any off-the-shelf antibody in a single step with an imaging agent. Our strategic collaboration with Oncodesign Services allows broader access to and usage of non-invasive imaging applications and provides an innovative solution to biotech and pharma partners to integrate imagery in the development of new antibody- and ADC-based therapeutics,' commented Frédéric Lévy, Chief Scientific Officer at Debiopharm. Aidan Synnott, CEO of Oncodesign Services, said, 'We are pleased to integrate this cutting-edge technology into our portfolio for our clients. The AbYlink™ technology gives the advantage of generating reproducible batches of bioconjugated antibodies and ADCs that secure specificity and efficacy of targeted radiotherapy.' About AbYlink™ AbYlink™ is a versatile and rapid regio-selective chemical conjugation technology for use to prepare diagnostic or therapeutic conjugates. This one-step method results in stable conjugation at defined and invariable sites on the Fc domain of an antibody or the like, with no impact on antigen-binding regions. It enables a seamless and reproducible conjugation of payloads (e.g., a chelator for radiolabeling, a fluorescent dye or a drug) to antibodies or ADCs. The universal applicability of the technology has been demonstrated for various antibody isotypes and payloads. About Debiopharm Research & Manufacturing Debiopharm Research & Manufacturing manufactures treatments for prostate cancer, breast cancer and precocious puberty, namely at its Martigny facility, where it employs two hundred people. It is a subsidiary of the pharmaceutical company Debiopharm, headquartered in Lausanne, Switzerland. Debiopharm is an innovative company, devoting over 90% of its resources to innovation and the development of new drugs. Its mission is to develop innovative therapies that target high unmet medical needs in oncology and infectious diseases. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds and technologies for in-licensing, clinically demonstrate their safety and efficacy, and then select pharmaceutical commercialization partners to maximize patient access globally. About Oncodesign Services Oncodesign Services is a contract research organization specializing in drug discovery and preclinical development. The company works with global biopharma partners to advance therapies in oncology, inflammation and infectious diseases through integrated services in protein sciences, structural biology, medicinal chemistry, pharmaco-imaging, DMPK and in vivo/in vitro pharmacology. Oncodesign Services has European facilities in France and the Netherlands. More information on the website Follow us on LinkedIn
Business Wire
22-04-2025
- Business
- Business Wire
Debiopharm to Reveal Insights From Their ADC, DDR Inhibitor, and Antibody Conjugation Technology Research at the 2025 AACR Conference in Chicago
LAUSANNE, Switzerland--(BUSINESS WIRE)--Debiopharm ( a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow's standard-of-care to cure cancer and infectious diseases and develop new antibody linker technologies, will release promising new data for two of its pipeline products at the 2025 Annual American Association for Cancer Research (AACR) meeting in Chicago, Illinois. Furthermore, a joint poster presentation with Oncodesign Services ( will highlight the applicability of its antibody conjugation technology, AbYlink™, in the preparation of conjugates for use in non-invasive preclinical imaging. Comprehensive preclinical results will be presented for Debio 1562M, a next-generation Antibody-Drug Conjugate (ADC) targeting the cell surface glycoprotein CD37 soon to undergo first-in-human evaluation. Two preclinical data releases will be included in the poster display sessions for Debio 0123, a selective WEE1 kinase inhibitor disrupting the DNA-damage response (DDR) of cancer cells. The first data release shows how Debio 0123 can be used in combination with the PKMYT1 inhibitor lunresertib as a promising therapeutic strategy in ovarian and breast cancer. The company will also unveil new impactful findings stemming from its collaboration with Genialis, showing how machine learning has the potential to enhance the ability to predict responders to Debio 0123, thus further advancing the understanding and application of WEE1 biology and response to inhibitors. Additionally, in the framework of a licensing agreement and a collaborative endeavor to support innovative research, Debiopharm and Oncodesign Services will present promising new data illustrating how AbYlink™ conjugation technology can facilitate the production of conjugates for use in preclinical research in cancer treatment. 'The pre-clinical results to be released during the AACR are laying a solid foundation for future research,' explained Angela Zubel, Chief Development Officer, Debiopharm. 'The two drug research approaches of ADCs and DDR inhibition are harnessing novel modalities and targets with the potential to outsmart hard-to-treat liquid and solid tumors, revolutionizing patient outcomes. Our AbYlink™ technology demonstrates great potential in the context of antibody radio conjugates against cancer and shows promise for broader use and wider applications.' Poster Session Title: Artificial Intelligence and Machine Learning for Therapeutic Election and Discovery AACR 2025 Poster Presentation Debiopharm compound Title Presenter -Mon, April 28 th -Poster display: 2:00-5:00pm -Abstract #3659 -Poster Section: 45 -Poster Board #: 21 Debio 0123 Biology-driven, machine learning-based development of a biomarker to predict response to WEE1 inhibitor Debio 0123 Kristian Urh, Genialis Expand Poster Session Title: Radiation Treatment Combinations for Tumors, Normal Tissue About DNA-Damage Repair (DDR) When cells have damaged DNA, they need to undergo a repair process called DDR to be able to survive. Cancer cells rely a lot on DDR as they divide and grow uncontrollably. Inhibition of DDR, particularly in combination with other anticancer agents, prevents cancer cells from repairing their DNA, which ultimately activates a self-destruction program in cancer cells. DDR inhibitors such as Debio 0123, a WEE1 inhibitor from Debiopharm, are being tested in clinical and preclinical studies. Debiopharm's ADC portfolio We're developing fit-for-purpose antibody drug conjugates through a tailored 'Trifecta' approach: strategic target selection, innovative Multilink™ linker technology and smart payload choices. Our broad and balanced portfolio of 1st-in-class and best-in-class ADCs includes Debio 0633 (undisclosed target), Debio 1562M, a CD37-targeted ADC for the treatment of acute myeloid leukemia (AML) Myelodysplastic syndromes (MDS), Debio 0532, an HER3-targeted ADC for solid tumors, as well as other ADCs for undisclosed targets including a proprietary bispecific ADC. Key partnerships also comprise options to in-licence bispecific antibodies targeting HER2-HER3 and HER3-EGFR along with other antibodies for undisclosed targets. To allow both high DAR and high stability, our ADCs are designed with our innovative proprietary Multilink™ linker technology. We're leveraging key collaborations and our in-house capabilities including ADC conjugation, optimization, PK/PD, toxicology, translational medicine, clinical development and supply chain to produce novel ADCs that respond to the high unmet needs of cancer patients. About AbYlink™ AbYlink™ is a versatile and rapid regio-selective chemical conjugation technology for use to prepare diagnostic or therapeutic conjugates. This one step method results in stable conjugation at defined and invariable sites on the Fc domain of an antibody or the like, with no impact on antigen-binding regions. It enables a seamless and reproducible conjugation of payloads (e.g. a chelator for radiolabeling, a fluorescent dye or a drug) to antibodies or ADCs. The universal applicability of the technology has been demonstrated for various antibody isotypes and payloads. Debiopharm's commitment to cancer patients Debiopharm develops innovative therapies that target high unmet medical needs in oncology and infectious diseases. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential assets and technologies for in- licensing, clinically demonstrate their safety and efficacy, and then select pharmaceutical commercialization partners to maximize patient access globally.
